Skip to content

Mace Consult launched as a new and independent business on 5 March 2026, through a carve-out from Mace Group. Mace Consult and Mace Construct operate as two independent businesses. Information, references and materials on this website may represent operations prior to this separation. Go to Mace Construct here.

Christie Proton Beam Therapy

Landmark cancer treatment centre is a first for the UK

Delivering cutting-edge care, close to home

Night render of the Christie Proton Beam Therapy building

Key takeaways

750

patient capacity for cutting-edge treatment annually

6

m thick walls to protect from radiation

150

tonnes of equipment delivered

  • Delivered the UK’s first NHS proton beam therapy centre that will benefit countless lives across the country. 
  • The main piece of equipment the Cyclotron, said to be as heavy as a Boeing 747, will enable the treatment of three patients simultaneously, five days a week.  
  • Collaborated on the Integrated Procedures Unit in tandem with the trust, co-locating radiology, procedure unit, pain service, plastic surgery, endoscopy, and day-case surgery.

We worked with the Christie NHS Foundation Trust on developing its new Proton Beam Therapy (PBT) Centre in Manchester, which will treat patients with a new kind of radiotherapy. 

The challenging build was designed in line with UK guidelines, with the full support of the UK’s Health and Safety Executive’s Radiation Protection Advisers. 

To ensure the hospital could remain fully functional throughout construction and avoid any disturbances to clinical activity, we worked with the trust and the main supplier to develop detailed logistics and construction plans that identified and resolved potential issues and challenges. 

Our appointment as project manager of the PBT centre’s construction under the NHS P21+ framework was one of many developments that we have delivered for the trust, with which we have had a long-standing relationship. In 2014, we completed the Palatine Treatment Centre, which incorporates a Young Oncology Unit and Haematology Transplant Unit. We are also currently working on its new Integrated Procedures Unit (IPU).

Mace Logo

Mace Consult and Mace Group are now two independent businesses.

In 2025, a majority investment in Mace Consult by Private Equity at Goldman Sachs Alternatives was announced through a demerger from Mace Group.

This completed on 5 March 2026, with Mace Consult and Mace Group (which includes Mace Construct) now independent businesses. To continue, please choose whether you want to explore Mace Consult or Mace Construct.